Literature DB >> 22948328

Current concepts and management strategies in chronic kidney disease-mineral and bone disorder.

Veeraish Chauhan1, Ellie Kelepouris, Nishtha Chauhan, Megha Vaid.   

Abstract

The term renal osteodystrophy describes the pathological changes in bone structure in chronic kidney disease (CKD); however, this term fails to describe adequately the adverse changes in mineral and hormonal metabolism in CKD that have grave consequences for patient survival. CKD-mineral and bone disorder (CKD-MBD) is a broader, newly defined term that should be used instead of renal osteodystrophy to define the mineral, bone, hormonal, and calcific cardiovascular abnormalities that are seen in CKD. The new paradigm in the management of renal bone disease is to "think beyond the bones" and strive to improve cardiovascular outcomes and survival. This means treating other aspects of the disease process that go beyond merely controlling parathyroid hormone levels. Primary physicians need to take a proactive approach to the management of CKD-MBD because the disorder begins early in the course of CKD, well before a patient is referred to a nephrologist. This review outlines the evidence behind the understanding of CKD-MBD, its implications for overall mortality, and the latest recommendations for management of CKD-MBD in patients with predialysis CKD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948328     DOI: 10.1097/SMJ.0b013e318261f7fe

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  5 in total

1.  Severe maxillofacial renal osteodystrophy in two patients with chronic kidney disease.

Authors:  Maria Luiza Diniz de Sousa Lopes; Assis Filipe Medeiros Albuquerque; Adriano Rocha Germano; Lélia Maria Guedes Queiroz; Márcia Cristina da Costa Miguel; Éricka Janine Dantas da Silveira
Journal:  Oral Maxillofac Surg       Date:  2015-03-19

2.  Forearm bone mass predicts mortality in chronic hemodialysis patients.

Authors:  Lidija Orlic; Ivana Mikolasevic; Zeljka Crncevic-Orlic; Ivan Jakopcic; Josipa Josipovic; Drasko Pavlovic
Journal:  J Bone Miner Metab       Date:  2016-07-27       Impact factor: 2.626

3.  Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.

Authors:  Bryan Krastins; Amol Prakash; David A Sarracino; Dobrin Nedelkov; Eric E Niederkofler; Urban A Kiernan; Randall Nelson; Maryann S Vogelsang; Gouri Vadali; Alejandra Garces; Jennifer N Sutton; Scott Peterman; Gregory Byram; Bruno Darbouret; Joëlle R Pérusse; Nabil G Seidah; Benoit Coulombe; Johan Gobom; Erik Portelius; Josef Pannee; Kaj Blennow; Vathany Kulasingam; Lewis Couchman; Caje Moniz; Mary F Lopez
Journal:  Clin Biochem       Date:  2013-01-08       Impact factor: 3.281

Review 4.  Role of the Wnt/β-Catenin Pathway in Renal Osteodystrophy.

Authors:  Sarah-Kim Bisson; Roth-Visal Ung; Fabrice Mac-Way
Journal:  Int J Endocrinol       Date:  2018-04-02       Impact factor: 3.257

5.  Toxicity Effect of Sub-Chronic Oral Administration of Class Bitters® - A Polyherbal Formula on Serum Electrolytes and Hematological Indices in Male Wistar Albino Rats.

Authors:  Kingsley C Patrick-Iwuanyanwu; Kpobari W Nkpaa
Journal:  J Xenobiot       Date:  2015-11-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.